Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $18.54, but opened at $19.00. Spyre Therapeutics shares last traded at $18.30, with a volume of 75,636 shares changing hands.
Wall Street Analyst Weigh In
SYRE has been the topic of a number of recent analyst reports. Wedbush reiterated an "outperform" rating and issued a $65.00 price objective on shares of Spyre Therapeutics in a report on Monday, January 13th. Wolfe Research initiated coverage on Spyre Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $27.00 price objective for the company. Finally, The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, February 18th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Spyre Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $50.86.
Check Out Our Latest Stock Report on Spyre Therapeutics
Spyre Therapeutics Stock Performance
The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -2.43 and a beta of 2.98. The firm has a 50-day simple moving average of $20.85 and a two-hundred day simple moving average of $25.94.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.08. As a group, equities analysts forecast that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.
Institutional Investors Weigh In On Spyre Therapeutics
Large investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Spyre Therapeutics during the fourth quarter worth approximately $29,000. Huntington National Bank acquired a new stake in shares of Spyre Therapeutics in the 4th quarter valued at $34,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Spyre Therapeutics during the 4th quarter worth $46,000. Quest Partners LLC grew its stake in shares of Spyre Therapeutics by 271.2% during the third quarter. Quest Partners LLC now owns 5,654 shares of the company's stock worth $166,000 after purchasing an additional 4,131 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in Spyre Therapeutics in the fourth quarter valued at $182,000. Hedge funds and other institutional investors own 80.39% of the company's stock.
About Spyre Therapeutics
(
Get Free Report)
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Further Reading
Before you consider Spyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.
While Spyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
